Dr. Reddy's Reports Q2 & H1 FY26 Results: Revenues Up, PAT Rises Amidst Strategic Growth
Dr. Reddy's reports Q2 & H1 FY26 consolidated revenues up 9.8% and 10.6% YoY, respectively. PAT grew 14% and 8% YoY. Strategic acquisitions and new product launches drive growth despite North America challenges.
This is a comprehensive quarterly and half-yearly financial results announcement, which is critical for investor decision-making. It includes detailed financial performance, management commentary, strategic business developments like acquisitions and product launches, and regulatory updates, all of which have a high impact on the company's valuation and market perception.
The announcement presents a mixed financial picture. While revenues and profit after tax (PAT) showed healthy year-on-year growth, profit before tax (PBT) and gross margins declined. The decline in North American generics due to price erosion and lower Lenalidomide sales is a negative, but strong growth in Europe, India, and emerging markets, coupled with strategic acquisitions and numerous product launches, provides positive momentum. The one-time VAT liability and impairment charges also impacted profitability.
* Dr. Reddy's Laboratories Limited announced its consolidated financial results for the quarter and half-year ended September 30, 2025. * Q2 FY26 Financial Highlights (Quarter ended September 30, 2025): * Revenues stood at ₹8,805.1 crore, marking a 9.8% year-on-year (YoY) and 3% quarter-on-quarter (QoQ) growth. * Profit after Tax attributable to Equity Holders increased by 14% YoY and 1% QoQ to ₹1,437.2 crore. * Profit before Tax (PBT) declined by 4% YoY and QoQ to ₹1,835 crore. * EBITDA was ₹2,351.1 crore, representing a 3% increase YoY and QoQ. * Diluted Earnings per Share (EPS) was ₹17.25. * H1 FY26 Financial Highlights (Half-year ended September 30, 2025): * Revenues reached ₹17,350.3 crore, an 10.6% increase YoY. * Profit after Tax attributable to Equity Holders grew by 8% YoY to ₹2,854.9 crore. * PBT decreased by 2% YoY to ₹3,739.7 crore. * Diluted EPS was ₹34.26. * Management Commentary: Co-Chairman & MD, G V Prasad, stated that Q2 growth was driven by momentum in branded markets and contributions from the Nicotine Replacement Therapy (NRT) portfolio, which helped offset the decline in U.S. Lenalidomide sales. The company remains focused on strengthening its core business, advancing pipeline assets, driving productivity, and pursuing business development initiatives. * Segmental Performance: * Global Generics revenues grew 10% YoY to ₹7,849.8 crore in Q2 FY26. * North America revenues declined 13% YoY to ₹3,240.8 crore due to increased price erosion in certain key products, including Lenalidomide. * Europe revenues saw a significant 138% YoY growth to ₹1,376.2 crore, largely driven by the acquired NRT portfolio and new product launches. * India revenues increased by 13% YoY to ₹1,578 crore, supported by price increases, new launches, and higher volumes. * Emerging Markets revenues rose 14% YoY to ₹1,654.8 crore, primarily due to new product launches and favorable forex. * Pharmaceutical Services and Active Ingredients (PSAI) revenues grew 12% YoY to ₹945 crore. * Key Business Highlights: * Acquired the STUGERON® portfolio for $50.5 million (₹446.4 crore) across 18 markets in APAC and EMEA regions. * Launched Linaclotide ('Colozo®') and Tegoprazan ('PCAB®') in India. * Partnered to make the HIV prevention tool, Lenacapavir, affordable in 120 low- and middle-income countries. * Received a positive opinion from EMA for a denosumab biosimilar candidate and IND acceptance for COVA 302 for ALS. * Launched Sacubitril Valsartan tablets (generic Entresto®) and fluorouracil cream (authorized generic of CARAC®) in the US. * Other Updates: The company received Form 483 with observations for several manufacturing facilities from the USFDA, with some outcomes classified as 'Voluntary Action Indicated (VAI)'. * Financial Details: Gross Margin declined to 54.7% in Q2 FY26. SG&A expenses increased due to investments and one-time expenses, including a potential VAT liability of approximately ₹70 crore. R&D expenses decreased by 15% YoY due to reduced investment in Biosimilars. * Other Financials: Operating Working Capital stood at ₹13,330 crore, Capital Expenditure at ₹510 crore, Free Cash Flow at ₹580 crore, and Net Cash Surplus at ₹2,750 crore as of September 30, 2025. Annualized Return on Capital Employed (RoCE) was 21.9%.
What to do with a filing like this
Dr. Reddy's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Reddy's Laboratories Limited. Read the original for the full detail.